Skip to content

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

ISSN 1875-9114, 0277-0008

8 papers in the library · 241 citations · publishing 1996-2024

Papers

Sort Most recent Most cited

Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy October 1, 2024 Atif Siddiqui 5 citations

Benzodiazepines and electroconvulsive therapy (ECT) are mainstay treatments for catatonia, a potentially life-threatening psychomotor syndrome characterized by a range of symptoms, including immobility, mutism, stupor, posturing, and sometimes even agitation. It can be a manifestation of various underlying psychiatric or medical conditions, such as schizophrenia, mood disorders, or neurological...

DOI: 10.1002/phar.4612 (opens in new tab) Full text (opens in new tab) Catatonia treatment Ketamine therapy Geriatric psychiatry Schizophrenia management +1

Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy July 2022 Thomas J Moore, Abdallah Alami, G Caleb Alexander et al.

Ketamine, an anesthetic available since 1970, and esketamine, its newer S-enantiomer, provide a novel approach for the treatment of depression and other psychiatric disorders. At subanesthetic doses, the two drugs, along with their older congener, phencyclidine (PCP), induce a transient, altered mental state by blocking the N-methyl-D-aspartate (NMDA) receptor for glutamate, the primary...

DOI: 10.1002/phar.2707 (opens in new tab) Full text (opens in new tab) Esketamine Drug approval Evidence-based toxicology Ketamine hydrochloride +1

Response to Intravenous Racemic Ketamine After Switch From Intranasal (S)-ketamine on Symptoms of Treatment-Resistant Depression and PTSD in Veterans: a Retrospective Case Series

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy February 5, 2022 Sean Bentley, Hewa Artin, Eamonn Mehaffey et al.

Racemic (R,S)‐ketamine is a glutamatergic drug with potent and rapid acting antidepressant effects. An intranasal formulation of (S)‐ketamine was recently approved by the US Food and Drug Administration (FDA) to be used in individuals with treatment‐resistant depression (TRD). There are no data directly comparing outcomes on depression or other comorbidities between these two formulations of...

“Not for Human Consumption”: A Review of Emerging Designer Drugs

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy April 8, 2014 Megan E. Musselman, Jeremy P. Hampton 85 citations

Synthetic, or "designer" drugs, are created by manipulating the chemical structures of other psychoactive drugs so that the resulting product is structurally similar but not identical to illegal psychoactive drugs. Originally developed in the 1960s as a way to evade existing drug laws, the use of designer drugs has increased dramatically over the past few years. These drugs are deceptively...

Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy September 1, 2006 William R Wolowich, Alisha M Perkins, John J Cienki 37 citations

To determine the content of the hallucinogen salvinorin A in a variety of Salvia divinorum herbal products and to compare the content with the label claims of potency and purity. Laboratory analysis. University-affiliated laboratory. Five herbal products containing Salvia divinorum. The samples were purchased from the Internet and local drug paraphernalia shops ("head shops"). Highperformance...

Putting an Ecstasy test kit to the test: harm reduction or harm induction?

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy October 2003 Rebecca A Murray, Paul L Doering, Lisa A Boothby et al.

To evaluate the DanceSafe Complete Adulterant Screening Kit for Ecstasy with regard to its accuracy in identifying 3,4-methylenedioxymeth-amphetamine (MDMA) and methylenedioxyamphetamine (MDA) derivatives and its ability to detect certain contaminants. In part 1, 39 street-grade tablets purported to be MDMA were tested with the Marquis, Mecke, and Simon's reagents provided by the DanceSafe...

A Comprehensive Review of MDMA and GHB: Two Common Club Drugs

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy December 1, 2001 Christian J. Teter, Sally K. Guthrie 114 citations

“Club drugs” have become alarmingly popular. The use of 3,4‐methylenedioxymethamphetamine (MDMA, Ecstasy) and γ‐hydroxybutyrate (GHB), in particular, has increased dramatically from 1997–1999. The pharmacokinetics of MDMA and GHB appear to be nonlinear, making it difficult to estimate a dose‐response relationship. The drug MDMA is an amphetamine analog with sympathomimetic properties, whereas...

DOI: 10.1592/phco.21.20.1486.34472 (opens in new tab) MDMA Ecstasy Rhabdomyolysis Gamma hydroxybutyrate +11

A Review of NMDA Receptors and the Phencyclidine Model of Schizophrenia

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy January 2, 1996 Sheri A. Thornberg, S. R. Saklad

Current models of drug‐induced psychosis insufficiently describe the symptoms of schizophrenia. Phencyclidine‐induced psychosis is a model that more completely reflects the pathophysiology of the disease. By decreasing glutamatergic neurotransmission, phencyclidine decreases 7‐aminobutyric acid release from the nucleus accumbens, striatum, and hippocampus (manifested by MK‐801); may inhibit...